Stem Cell Therapeutics Corp. Announces Enrollment of First Patient in the Traumatic Brain Injury Trial
April 28 2011 - 6:54PM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") is pleased to announce the enrollment of the first
patient in the SCT supported Open label Phase IIa traumatic brain
injury ("TBI") trial entitled "A Phase IIa, Single Center, Open
Label Study to Characterize the Safety of Human Chorionic
Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain
Injury". The principal investigator for this investigator-led
clinical trial is Dr. David Zygun at the Foothills Hospital. The
purpose of this trial is to characterize the safety profile of
NTx®-428 when administered to patients who have sustained a TBI.
Additionally, a number of secondary endpoints will be studied,
these include preliminary characterization of magnetic resonance
imaging, motor, cognitive and functional recovery. The trial is
anticipated to complete the enrollment of 10 patients by year end
2011.
Dr. Allen Davidoff, Chief Scientific Officer of SCT commented,
"We congratulate Dr. Zygun and the emergency care team at Foothills
Hospital for their tireless efforts in screening that resulted in
the enrollment of this first patient in the TBI trial. SCT's
management is equally excited that the NTx®-428 clinical program
takes an important step forward toward demonstrating the safety and
effectiveness of this regimen in TBI. Broadening our knowledge of
the applicability of hCG and EPO into other areas of acute
neurologic injury, in addition to stroke, is anticipated to
substantially increase the technology value of this program."
Dean Peterson, Chairman of the Board of SCT commented, "SCT is
excited to have enrolled its first TBI patient, reaffirming the
board and management's commitment to moving forward as a
biotechnology company and adding value to its intellectual property
portfolio. The board and SCT management are actively working on
various initiatives and SCT continues to appreciate the ongoing
support of its shareholders."
About Stem Cell Therapeutics Corp: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX-V: SSS) focused on
the development and commercialization of drug-based therapies to
treat central nervous system diseases. SCT is a leader in the
development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as stroke,
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Michael Cook CFO
403-245-5495 ext.229 mcook@stemcellthera.com Stem Cell Therapeutics
Corp. Allen Davidoff, PhD CSO 403-245-5495 ext. 226
adavidoff@stemcellthera.com Stem Cell Therapeutics Corp. Angelika
Goncalves DaSilva Operations Manager 403-245-5495 ext. 221
adasilva@stemcellthera.com www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024